UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________________________________________________

FORM 8-K

______________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~the~~Report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported): November 5, 2025

~~Date of Report (Date of earliest event reported): October 15, 2025~~______________________________________________________

Dynavax Technologies Corporation

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-34207		33-0728374
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

______________________________________________________

2100 Powell Street, Suite 720
Delaware		001-34207	33-0728374
Emeryville, CA	94608
(State or Other Jurisdictionof Incorporation)		(Commission File Number)	(IRS EmployerIdentification No.)
(Address of Principal Executive Offices)	(Zip Code)
2100 Powell Street, Suite 720
Emeryville, CA			94608
(Address of Principal Executive Offices)			(Zip Code)


Registrant’s Telephone Number, Including Area Code: (510) 848-5100

(Former Name or Former Address, if Changed Since Last Report)

______________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

~~Trading Symbol(s)~~

~~Name of each exchange on which registered~~

TradingSymbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

~~DVAX~~

~~Nasdaq Global Select Market~~

DVAX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐o

Item 5 2.02 ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

InOn ~~connection with an internal realignment of various management roles and responsibilities, on October~~November 155, 2025, ~~the Board of Directors (the “Board”) of~~ Dynavax Technologies Corporation (~~the “Company”~~"Dynavax") ~~approved~~issued ~~the~~a ~~transition~~press ofrelease ~~David~~announcing F.its ~~Novack~~financial ~~from~~results ~~his~~for ~~roles as~~ the ~~Company’s~~third ~~President~~quarter ~~and~~ended ~~Chief Operating Officer to his new roles as Senior Vice President and Chief Operating Officer, effective January~~September 130, ~~2026~~2025. ~~The~~A ~~Board~~copy ~~also~~of ~~approved~~ the ~~removal~~press ofrelease ~~Robert~~is ~~Janssen,~~attached ~~M.D.’s roles~~ as ~~Chief~~Exhibit ~~Medical~~99.1 ~~Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs, effective upon the earlier~~ to ~~occur~~this ofcurrent ~~(a) the~~report ~~date the Company employs a new Chief Medical Officer~~ and ~~(b) March 2,~~is ~~2026,~~incorporated ~~and~~herein ~~further~~by ~~approved the conclusion of Dr~~reference. ~~Janssen’s~~ ~~employment as of March 2, 2026.~~

The ~~Company~~information ~~has~~with ~~commenced~~respect ato ~~search~~item ~~process~~2.02 in this current report and its accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) ~~successor~~of ~~Chief~~the ~~Medical~~Securities ~~Officer~~Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is furnished herewith:


99.1			Press release dated November 5 , 2025 titled "Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program ."
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			~~Dynavax Technologies Corporation~~	Dynavax Technologies Corporation
Date: October 15, 2025		By:	/s/ John Slebir
Date:	November 5, 2025		By:	/s/ Kelly MacDonald
			John Slebir Senior Vice President, General Counsel
				Kelly MacDonaldSenior Vice President, CFO

Filing Compare · DYNAVAX TECHNOLOGIES CORP